Abstract: Sexually transmitted diseases (STDs) continue to be a global epidemic with significant risk of morbidity/mortality for the fetus. STDs with prominent cutaneous findings including condylomata acuminata, genital herpes infections, and syphilis are reviewed. Important clinical cutaneous findings help aid early diagnosis and facilitate treatment. Condylomata acuminata have the potential of causing cervical cancer, anogenital cancer, and oropharyngeal cancer. Significant advances have been made in human papilloma virus vaccinations and treatment. Genital herpes infection can produce significant physical and emotional distress to the patient and significant potential harm to the fetus. Early clinical recognition of STDs and their appropriate management is critical.
Sexually transmitted diseases (STDs) have been epidemic at the global level and can have significant morbidity and mortality for the fetus. There has been an expanding knowledge of the epidemiology of these diseases as well as advances in vaccines and management. The STDs that have the most significant cutaneous aspects will be discussed, including condylomata acuminata (CA) due to human papilloma viruses (HPV), herpes simplex viruses (HSV), and syphilis. Each therapy reviewed in this section will be assigned a letter from A (most evidence) to E (least evidence). An A designation represents at least 1 prospective randomized, double-blinded, controlled trial or meta-analysis, whereas B represents clinical trials with >20 subjects, but lacks adequate controls. C represents small trials with <20 subjects, but design limitations or large number of case reports and D reflects at least 5 cases reported in the literature and E has only anecdotal case reports or <5 cases (as modified by Bartlett and Tyring 1 ). CA key points: HPV subtypes 6 and 11 are low risk and rarely give rise to cervical cancer, but may be responsible for 90% of genital warts. 2 HPV subtypes 16 and 18 are high risk and strongly associated with cervical dysplasia and found in 70% of squamous cell carcinomas of the cervix. 2 Cesarean delivery is indicated for women with genital warts primarily if the pelvic outlet is obstructed or there are concerns for excessive bleeding. HPV vaccines may play a significant role in reducing the burden of disease, but vaccination at a younger age (10 to 13 y) may be more preventative than vaccination at a later age.
The virus can infect squamous cells located in the skin, oral, vaginal, anal, and nasal epithelium. Viral replication is restricted to the basal cell layer of surface tissues. 2 After inoculation, CA are spread either by direct contact from person to person or indirectly by contact from contaminated surfaces or objects. 3 The complications of HPV infection include genital warts, cervical cancer, other anogenital cancers (anal, vaginal, vulvar, and penile), oropharyngeal cancer, and recurrent respiratory papillomatosis. 3 It has been estimated that between 500,000 to 1 million new cases of genital warts are diagnosed each year in the United States. 2 
Virology
The HPV viral group represents a nonenveloped, double-stranded DNA virus. There are >130 different subtypes of HPV with some infecting the mucosal epithelium and others cutaneous epithelium. Approximately 40 different subtypes appear to infect the anogenital tract. 2 The majority of anogenital warts are caused by low-risk types of HPV (LR-HPV), commonly HPV types 6 and 11. 4 Other LR-HPV types, such as HPV 42 and 81, are also common. 3 Highrisk HPV (HR-HPV) subtypes include 16 and 18, which can integrate viral DNA within the host's genome, promoting transcription of oncoproteins that inactivate tumor suppressor genes. 2 The oncogenic potential is based on the ability of the viral DNA to integrate into the host genome and control regulation of native genes. Scientific investigation has elucidated that the viral genome is composed of 6 early-open reading frames (E1, E2, E4, E5, E6, E7) and 2 lateopen reading frames (L1, L2). It appears that the early-open E genes are critical for regulatory function and encode the proteins necessary for viral replication and cell transformation. 2 After incorporation in the host cell genome, viral subparticles E6 and E7 are able to replicate without regulation and interfere with normal host cellular growth and regulation. Immunocompromised patients have a higher prevalence of coinfection with HR-HPV, especially HPV 16 (Table 1) . 4 
Epidemiology
The prevalence of HPV infection has risen over the past 35 years, in part due to an earlier age of initial sexual exposure and an increasing number of sexual partners. 2 In women, the main risk factors for genital infection include: acquisition of new male partners; an increasing number of lifetime sexual partners, both in females and their male partners; and having nonmonogamous male partners. 5 Sexual contact with an individual infected with HPV results in a 75% chance of contracting the virus and developing condyloma. 2 The peak incidence in females is 24 years. Although sexual contact is the most common mode of transmission, HPV DNA has been isolated from underwear and towels and these a potential source of transmission. Laser plumes and inadequately sterilized instruments can also be a source for spread. 3 The vertical transmission of HPV to infant during delivery or in utero is an import mode of transmission and can lead to laryngeal papillomatosis.
Clinical Presentation
After initial infection, there is an incubation period of 3 weeks to 8 months before clinical evidence of the disease. The average timeframe for presentation is approximately 2 to 3 months after initial exposure. 2 Initial presentation is often at sites traumatized during intercourse, especially in areas that are moist. The appearance of CA is highly variable in appearance and color. Early lesions are often small, flat, or skin colored, dome-shaped papules, 1 to 3 mm in diameter. CA often coalesce into larger plaques and take on a cauliflower appearance or become pedunculated. The color can range from white, gray, red, tan, or brown. In women, CA can develop at the fourchette, labia minora, labia majora, pubis, clitoris, urethral meatus, perineum, perianal region, anal canal, introitus, vagina, and ectocervix. 6 Symptoms associated with CA include burning, pruritus, bleeding, and severe discomfort. 2 During pregnancy, the CA can increase in size and number and potentially obstruct the genital tract with increased viral shedding (Fig. 1) . 3 Giant exophytic cauliflower-shaped CA are referred to Bushke-Lo¨wnstein tumors and are usually associated with HPV types 6 and 11 (Fig. 2) . The histologic appearance suggests a well-differentiated verrucous carcinoma. 3 They do not metastasize, but have the potential for expansive and invasive growth. Malignant transformation occurs in up to 50%. 4 Bowenoid papulosis has a distinctive reddish-brown papular appearance. They are now considered a low-grade carcinoma in situ and can be managed by locally destructive treatments. 
Clinical Concerns
A potential risk of maternal CA is vertical transmission to the infant that can result in laryngeal papillomatosis. Recurrent laryngeal papillomatosis is rare, affecting 4.3/100,000 infants and children in the United States. 7 Infants at risk are those born vaginally to young women, who have higher infection rates with CA-associated HPV strains, with longer labors. Because of the relative frequency of HPV infection and the relative rarity of this condition, there is no recommendation for abdominal delivery in women with CA. The CDC states, ''Cesarean delivery is indicated for women with genital warts if the pelvic outlet is obstructed or if vaginal delivery would result in excessive bleeding.'' 8 In clinical practice, the patient with CA that would require cesarean is rare. CA can be safely treated during pregnancy with topical tricholoracetic acid or surgical modalities (laser or cryotherapy), 2 but many warts will regress after delivery. The most effective way to prevent this disease is through vaccination. Limited population registries have shown that vaccination at younger age (10 to 13) was more effective at preventing CA than vaccination at a later age. 9 HPV can be an important subclinical condition. Infection of the ectocervix can cause cytologic abnormalities that are detectable on routine cytologic screening (Pap smear). Flat condyloma of the cervix are virtually indistinguishable from mild dysplasia (low-grade squamous intraepithelial lesion) by either inspection or colposcopic examination. Cytologic changes apparent on Pap testing could be due to nononcogenic strains of HPV. Cervical cytologic abnormalities caused by nononcogenic strains of HPV are not associated with genital malignancies and testing for these low-risk strains is not clinically indicated. 10 It is clearly recognized that infection with HR-HPV is the requisite step for genital malignancies. Current guidelines recommend screening women (greater than 30 y of age) for HR-HPV and vaccination programs against some HR-HPV strains has had significant impact on HPV infection and severe cancer precursors rates.
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Management
There are many treatment options for the management of CA which focus more on local destruction of the lesions rather than elimination of the underlying virus. Some treatments are self-administered by the patient, whereas other destructive methods are performed only by a health care provider. There is little evidence to support that any existing treatments for CA can produce long-term eradication or prevent potential malignant transformation. 2 The treatments vary widely in their cost, convenience, side effects, and efficacy (Table 2) .
Patient Initiated Therapies
PODOPHYLLOTOXIN (A)
Podophyllotoxin is a purified extract of the podophyllum plant, which is able to bind cellular microtubules and inhibit mitotic division. 2 Podophyllotoxin is available as a 0.05% solution or gel and 0.15% cream. The medication is applied by the patient twice daily for 3 consecutive days, www.clinicalobgyn.com followed by a 4-day rest period for up to 4 weeks. Vulvar and anal warts are more efficiently treated with the 0.15% podophyllotoxin cream. 6 A review of published clinical data have reported clearance rates of 45% to 83% with the 0.05% solution and 43% to 70% with the 0.15% podophyllotoxin cream. 6 The adverse effects include local burning, itching, pain, and erosions. Podophyllotoxin is contraindicated during pregnancy and women of childbearing age should use contraception.
SINECATECHINS (A)
Sinecatechins are an extract from green tea (camellia sinensis) and contains epigallocatechin gallate, which has potent activity against virally infected cells. The product is available as a 15% ointment for the treatment of external genital warts and perianal warts in immunocompetent patients over 18 years of age. The patient applies the ointment 3 times a day for up to 16 weeks. Patients may experience minor itching, redness, and pain. The exact mechanism of action is unknown, but sinecatechins demonstrated growth inhibitory potential against HPV-infected tumor cell lines attributed to induction of apoptosis. A review of published clinical trials have demonstrated clearance rates of 47% to 59% over 12 to 16 weeks. 6 The treatment should not be used in pregnancy.
TOPICAL IMIQUIMOD 5% CREAM (A)
Imiquimod 5% cream is an immune response modifier, which is indicated for the topical treatment of anogenital warts in immunocompetent patients. It is a tolllike receptor agonist, which induces the production of local cytokines, resulting in increased acquired and cellular immunity. Interferon-a, tumor necrosis factor-a, and interleukins 1, 6, 8, 10 , and 12 are all stimulated. This leads to tissue-specific apoptosis of viral-infected keratinocytes and results in viral load reduction of HPV types 6 and 11. Imiquimod cream 5% is dispensed as a package of 12 single-use sachets. The cream is applied topically to the condyloma 3 times a week at bedtime and washed off the next morning until clearing of the condyloma or a maximum of 16 weeks. 2 Local inflammatory reactions are common and include pruritus, irritation, tenderness, ulceration, and pain. Some patients experience systemic side effects, such as myalgias, fatigue, headaches, and generalized malaise. 2 A review of published studies demonstrated complete clearance rates of up to 56%. Women appear to respond better than men and had a shorter median time to clearance. 2 Topical imiquimod 5% cream appears to be an effective treatment modality for HPV 6 and 11 vulvar warts. The use of topical 5% cream for external genital warts in pregnant women has been reported, but the safety is unknown.
TOPICAL IMIQUIMOD 3.75% CREAM (A)
The Food and Drug Administration (FDA)-approved imiquimod 3.75% cream for the treatment of genital warts in 2010. The drug is available as a 7.5 G pump that dispenses 0.235 g of cream per application. Imiquimod cream 3.75% is dosed daily for 2 weeks of treatment, followed by a 2-week rest period, and then 2 more weeks of treatment. The mechanism of action is identical to the 5% cream and is an agonist of toll-like receptor-7. Advantages of the 3.75% cream, compared with the 5% formulation is less local irritation, lack of systemic symptoms, shorter duration of treatment, and better patient compliance. Overall, the 3.75% cream may be less effective than the 5% formulation, but better tolerated. 2 Females exhibited a better response rate than males. Clinical trials with imiquimod 3.75% cream have shown clearance between 28% and 33%.
Destructive and Surgical Management
There are many locally destructive methods to eradicate CA. These include, along with level of evidence rating, trichloroacetic acid (B), cryotherapy (B), electrosurgery (B), scissor excision (B), and CO 2 laser (B). 2 In general, the techniques are relatively effective, producing minimal scarring and some discomfort. Cryotherapy, trichloroacetic acid and surgical treatments can be done during pregnancy.
HPV Vaccines
The first FDA-approved HPV vaccine Gardasil (Merck and Company, Whitehouse Station, NJ) was approved in 2006. It is a quadravalent HPV recombinant vaccine for LR-HPV 6 and 11 and HR-HPV 6 and 18.
2 Gardasil is indicated for the prophylactic treatment of girls and young women between 9 and 26 years of age. The intent is to prevent HPV pathologic complications from HPV 16 and 18. Human antibodies to 6, 11, 16, 18 HPV subtypes are stimulated by the vaccine. It is 99% effective in preventing genital wart formation in patients naive to HPV infection. These HPV subtypes are responsible for 90% of genital warts and 70% of cervical cancers. In 2009, the bivalent HPV recombinant vaccine Cervarix (Glaxo Smith Kline, Research Triangle Park, NC) was approved by the FDA. 2 This vaccine stimulates antibodies against the oncogenic strains HPV 16 and 18 (Table 3) . 2 Genital herpes key points: There is an increasing incidence of genital herpes infections (GHI) caused by HSV type 1. Most HSV transmission occurs due to asymptomatic viral shedding. HSV 1-seropositive individuals are more likely to develop asymptomatic HSV 2 infection. 12 Immunocompromised patients often present with HSV infections that are more severe, atypical, chronic, and acyclovir resistant. Pregnant women with primary GHI are 10 to 30 times more likely to transmit the virus to the newborn than women with recurrent infections. GHI are one of the most common STDs with significant morbidity and mortality worldwide. 12 Women are twice as likely to contract herpes infections as men. Women also carry the potential risk of vertical transmission of herpetic infections to the neonate at the time of delivery. Women with GHI often have adverse psychological reactions that can impact their sexuality. Unfortunately, there is no specific antiviral strategy that can completely eradicate latent infections or inhibit viral reactivation, which makes managing this disease challenging.
Virology
GHI are due to HSV types 1 and 2 (HSV 1, 2). The viral structure contains a linear double-stranded DNA, an icosahedral capsule (100 to 110 nm in diameter), and an envelope containing glycoprotein spikes on its surface. 13 The infection is 
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spread following skin to skin or skin to mucosal contact. HSV enters epithelial cells in the mid-to-basal epidermis, replicates, and spreads to adjacent cells.
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After replication, the virus travels by retrograde axonal flow to the dorsal root ganglion and establishes latency until reactivation. 13 Reactivation leads to anterograde HSV transport in neuronal axons to overlying epidermal cells with subsequent viral replication. Reactivation and viral shedding episodes are frequent and typically asymptomatic. HSV 2 has shown greater efficiency than HSV 1 to reactivate and replicate in the genital tract. 12 Although there is a higher risk of transmission of HSV when genital lesions are active, most HSV transmissions occur when patients are asymptomatic. 12 Patients with primary genital HSV 2 infections experience an HSV reactivation 89% of the time and have a median of 4 recurrences a year. In contrast, patients with primary genital HSV 1 infections experience a 57% recurrence rate with a median of 1.3 recurrences per year.
14 Frequent brief viral shedding episodes, which are often asymptomatic, contribute to high HSV transmission rates. Reinfection with a second HSV strain may occur in some individuals. 12 Epidemiology GHI in the past have been attributed primarily to HSV 2 with a smaller percentage associated with HSV 1. Recent epidemiological studies have demonstrated an increasing proportion caused by HSV type I.
14 HSV-seronegative women from 18 to 30 years of age enrolled in the control arm of a herpes vaccine trial were followed for 20 months for the development of primary HSV genital infections. The rate of infection in the control arm for HSV 1 was more than twice that for HSV 2. The HSV 2 infection rate was 2.6 times higher in non-Hispanic blacks than Hispanics and 5.5 times higher than non-Hispanic whites.
15 HSV 1 genital infections are particularly rising among college students, young heterosexual women, and men having sex with men. 12 Although HSV 2 seroprevalance has decreased overall in the United States over the past several years, the decrease was most marked among non-Hispanic whites. Non-Hispanic black females showed only a slight decrease in HSV 2 seropositivity. Because of the chronic nature of HSV 2 genital infections, the prevalence increases with age and is especially common among middle aged, unpartnered women.
Clinical Manifestations of Genital Herpes Simplex Infections
The most pronounced clinical presentations occur with primary GHI, which are associated with large quantities of viral replication. In females, the lesions usually present bilaterally on the vulva, but the cervix is often involved. Other common sites of involvement include the perineum, vagina, and buttocks. Approximately 2 to 12 days after exposure, there is the onset of painful grouped vesicles or papules on an erythematous base, followed by crusting, erosion, and ulceration (Fig. 3) . Many patients have a prodrome of malaise. Healing of the lesions and resolution of symptoms typically occurs within 4 weeks. Recurrent lesions can be associated with a similar prodrome, but the lesions are fewer in number and less severe. 13 The severity of primary infections and frequency of complications is statistically higher in women than in men. Systemic complaints are greater in women. Urinary retention can be encountered in 10% to 15% of females and aseptic meningitis is approximately 10%. A sacral radiculomyelitis may occur with neuralgia, urinary retention, and meningoencephalitis. 13 In immunocompromised patients, the clinical manifestations may be very severe and chronic in nature. Patients often demonstrate chronic enlarging ulcerations or atypical lesions, which are pustular, follicular, verrucous, or exophytic. Atypical presentations are especially common in patients with HIV infection, hematopoietic stem cell or solid organ transplants, or leukemia/lymphoma. 13 The innate and adaptive immune responses play an important role in controlling HSV infection. CD4 + and CD8 + T cells predominate in attenuating HSV infection. 12 
Diagnosis of Genital HSV Disease
HSV infections can be detected by viral culture, polymerase chain reaction (PCR) assay and direct fluorescent antibody assays. Viral cultures from genital lesions can have low sensitivity, especially for recurrent or healing lesions. PCR assays for HSV DNA are being used more often for diagnosis due to increased sensitivity. PCR analysis may be available within 24 hours, whereas viral cultures take 2 to 5 days to grow. Direct fluorescent antibody assay is often used as an initial diagnostic test due to increased sensitivity and ability to distinguish between HSV and VZV. 13 
Exposure of Neonate to Genital Herpes During Delivery
The mother's previous immunity to HSV is critical in determining the risk of transmitting HSV to an infant during delivery. Women with primary genital herpes and high levels of viral shedding at the time of delivery are 10 to 30 times more likely to transmit HSV to the newborn compared with a mother with a recurrent infection. 16 Transmission of HSV to the neonate can occur with apparent genital lesions or asymptomatic viral shedding. HSV 2 seronegative pregnant women with HSV 2 seropositive sexual partners are especially at risk of developing primary genital herpes during the pregnancy. Of concern, two thirds of women who contract genital herpes during their pregnancy remain asymptomatic and have no apparent genital lesions.
The transmission of HSV infection to the newborn can be acquired intrauterine (in utero), intrapartum (prenatal), and postpartum. The overwhelming transmission occurs intrapartum. 16 There are 5 factors that impact transmission of HSV from mother to neonate: (1) type of maternal infection (primary vs. recurrent); (2) maternal HSV antibody status; (3) duration of rupture of membranes; (4) integrity of mucocutaneous barriers; and (5) mode of delivery (cesarean vs. vaginal delivery). 16 Cesarean delivery should be 
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www.clinicalobgyn.com performed, if genital HSV lesions are present or prodromal symptoms are present at the time of delivery to reduce the risk of neonatal HSV infection. 17 The role and impact of oral acyclovir and valacyclovir near the end of pregnancy to suppress genital HSV recurrences is being evaluated.
Management
There is no cure for genital HSV infections and treatment should be focused on reducing recurrences and transmission. Acyclovir, famciclovir, and valacyclovir are the mainstays of treatment. These are nucleoside analogues which inhibit viral DNA polymerase. During primary infections, they can be administered 7 to 10 days and 1 to 5 days for recurrences. Daily suppressive therapy to reduce symptomatic recurrences has been reported (Table 4) . Although these medications lower viral shedding and reduce severity of the lesions, they do not completely eliminate shedding or transmission. 12 Immunocompromised patients often demonstrate more frequent recurrences and more severe and longer lasting lesions. The choice of therapy should be based on considering cost of therapy and compliance. Drug resistance to acyclovir and related medications can occur among immunocompromised hosts, including HIVinfected patients. Acyclovir-resistant infections can be managed by second-line drugs, including foscarnet and cidofovir. 13 Saline compresses, along with analgesia can provide supportive care. Although topical lidocaine products are reasonably safe to reduce the pain of GHI, benzocaine should be avoided because it is a potent sensitizer. Counseling is important to reduce the risk of sexual and perinatal transmission. It is important to have frank discussions about subclinical viral shedding and limited benefit of condoms. Patients may require psychological counseling due to the severe psychological impact of recurrent disease. Patients with primary GHI should be given oral therapy, if they present within 5 days of the start of the episode or have new lesions forming. Topical antiviral therapies are less effective and have been associated with acyclovir-resistant strains. 18 Therapy should be initiated promptly, even before laboratory confirmation of the diagnosis. The following treatment protocols have been reported: acyclovir 400 mg 3 times a day or 200 mg 5 times a day; valacyclovir 1000 mg twice a day or famciclovir 250 mg 3 times a day for 7 to 10 days. 1 In HIV patients with primary GHSV, there are no controlled trials on duration or dosage of treatment. A 10-day course of therapy at twice the standard dose has been advocated. 18 
TABLE 4. Management of Genital HSV Infections
Type of Infections Treatment
Primary Recurrent GHIs are self-limited and less symptomatic. Management decisions are based on symptoms, frequency, and sexual partner status. Oral acyclovir, valacyclovir, and famciclovir are effective at reducing severity and duration of lesions. The recommended regimens are for 5 days: acyclovir 200 mg 5 times a day; acyclovir 400 mg 3 times a day; valacyclovir 500 mg twice a day, or famciclovir 125 mg twice a day. 18 Short-course therapies have also been described: Acyclovir 800 mg 3 times a day for 2 days, famciclovir 1 g twice a day for 1 day, or valacyclovir 500 mg twice a day for 3 days. 18 Suppressive therapy was initially recommended for patients with a recurrence rate of >6 recurrences per year. The frequency of recurrence at which suppressive therapy should be initiated is a subject of debate, based in part on cost and inconvenience of treatment. It may be worthwhile to periodically assess the need for continuing therapy. Regimens for suppressive therapy that have been reported include: acyclovir 200 mg 4 times a day, acyclovir 400 mg twice a day; valacyclvir 500 mg twice a day, and famciclovir 250 mg twice a day. 18 Short courses of suppressive therapy could be considered for vacations, special events, and examinations. The most important role of suppressive therapy is use among heterosexual HSV 2 discordant couples. 1 There is ongoing research looking at other management approaches in HSV. A microbicide vaginal tenofovir 1% gel was shown in a clinical trial to reduce the acquisition of HSV 2. This agent will require further study, but the initial trial is promising. There has been recent focus on the development of prophylactic HSV vaccines. A prophylactic HSV vaccine would help reduce the burden of genital HSV infections. Unfortunately, despite advances in HSV vaccine research, there have been roadblocks in the design of an effective prophylactic HSV vaccine. 12 Syphilis key points: Since 2001 the rates of primary and secondary syphilis have continued to rise, especially among men who have sex with men. Syphilis on a global level contributes a substantial burden of adverse pregnancy outcomes. Over 1 million pregnancies are affected worldwide. Penicillin G remains the treatment of choice for all stages of syphilis. Syphilis partner services are presumptive treatment of contacts based on exposure history is important in controlling the spread of the disease. 19 
Early Syphilis
After reaching historic new lows in reported cases in the United States in 2000, syphilis has shown a significant resurgence. On a worldwide basis, syphilis occurring during pregnancy and congenital syphilis remains a focus of concern.
Bacteriology
Syphilis is a spirochetal bacterium that belongs to the Treponema subspecies pallium. T. pallidum is a cylindrical shaped coiled organism, which is highly motile. The organism manifests 6 to 14 spirals. Humans are the only host and the infection is transmitted by sexual contact or congenitally. 19 
Epidemiology
Since 2001, there has been an epidemic resurgence in the rates of primary and secondary syphilis, especially with men having sex with men. There has also been an increase in low socioeconomic black heterosexual subpopulations in the Southeast United States. 19 The World Health Organization estimates 11 million new cases of syphilis each year on a global level. 20 Worldwide, >1 million women with active syphilis become pregnant each 19 Adverse pregnancy outcomes can be reduced by screening pregnant women and treating positive patients with a single dose of penicillin before 28 weeks' gestation. The clinical utility and cost of repeating syphilis testing in the third trimester of pregnancy has been studied in high-risk urban populations, but may not be cost-effective.
Clinical Manifestations
PRIMARY SYPHILIS
The chancre is the skin lesion which is the hallmark of primary syphilis. Typically, the chancre starts as a painless papule that rapidly evolves into an ulcer that has a clean base and is nonexudative (Fig. 4) . The chancre of primary syphilis usually manifests 1 week to 3 months (median, 21 d) after exposure at the site of inoculation. Often there is nontender regional lymphadenopathy. 19 Multiple chancres suggest possible HIV infection. In women, the most common sites of involvement are the perineum, anus, rectum, cervix, vagina, oropharynx, and lips. It is important to differentiate the genital ulcers of primary syphilis from HSV, chancroid, lymphogranuloma venerium, trauma, fixed drug reactions, and a neoplastic process. 19 
SECONDARY SYPHILIS
Secondary syphilis can sometimes be challenging to recognize. Many patients do not remember a primary lesion. The skin lesions of secondary syphilis typically manifest 2 to 8 weeks after the disappearance of the chancre, but sometimes the chancre persists. Individual skin lesions are often reddish-brown in color with fine scale and may be maculopapular or annular plaques. Extensive areas of the trunk and extremities are involved and there is often involvement of the palms and soles.
It is important to recognize the mucocutaneous features of secondary syphilis. Condylomata lata are moist verrucous plaques that predominate in intertriginous areas. Regions such as the inquinal creases, vulva, and perianal area are often involved. Condyomata lata can be very difficult to distinguish from condyloma acuminata due to HPV. The inner labia, prepuce, and oral mucosa may manifest mucous patches, which are superficial gray-white, eroded plaques. They can be misdiagnosed as candidiasis. Another unusual clinical finding is split papules, which are fissured papules at the angles of the lips that often look like warts. The mucocutaneous lesions of secondary syphilis contain high concentrations of spirochetes and are highly contagious. 19 Patchy alopecia of the scalp and eyebrows is an uncommon finding.
Patients with secondary syphilis often complain of fever, malaise, pharyngitis, and headache. Lymphadenopathy may be detected. Possible systemic findings include early neurological complications, periostitis, hepatitis, and glomerulonephritis. 19 
EARLY LATENT SYPHILIS
Early latent syphilis represents an asymptomatic period during the first year after the syphilis infection has occurred. Although serologic tests are positive, there are no clinical signs.
DIAGNOSIS OF SYPHILIS
Blood serological tests for syphilis, along with clinical features remain the diagnostic standard. At least 1 treponemal antigen test and 1 nontreponemal antigen test area sufficient to confirm syphilis. The most widely used nontreponemal antigen tests are the Venereal Disease Research Laboratory (VDRL) and Rapid Plasma Reagin (RPR). Although equally valid assays, they cannot be compared directly. Test results should be given quantitatively for 2 important reasons. The titers of the VDRL and RPR correlate with disease activity and are used the assess treatment response. The decline in these titers after treatment and compared with baseline is a guide to treatment response. 20 Overall, the nontreponemal tests have a sensitivity of 86% in primary syphilis and 100% in secondary syphilis. 19 Treponemal tests are also needed for confirm the diagnosis of syphilis. These tests include the treponema pallidum haemaglutinatim test, Fluorescent Treponemal Antibody Absorption Test (FTA-ABS), Treponema Pallidum Patricle Agglutination. Some new Enzyme Immunoassays have been developed, which detect total antitreponemal antibodies (IgG and IgM). Several commercially available kits have been developed. 20 Treponemal-specific tests confirm the diagnosis of syphilis and rule out false positives. These tests also remain positive during the lifetime of the patient, irrespective of treatment. They are 100% sensitive and 99% specific in secondary disease. 19 Many blood banks and laboratories are using treponemal Enzyme Immunoassays as a cost-effective initial screening test for syphilis. 19 Treponemal antigen tests, such as the treponema pallidum haemaglutinatim test or FTA-ABS are recommended for initial screening, which identifies patients with both previously treated as well as incompletely or untreated syphilis. Patients with a positive treponemal test should have a standard nontreponemal test (VDRL) to confirm the diagnosis. 19 In evaluating a patient for primary syphilis, dark-field microscopic examination should be done, if available, on any genital ulcer. Both a serum nontreponemal test (RPR or VDRL) and a treponemal test (TPP or FTA-ABS) should be performed. The treponemal tests may be nonsensitive in early disease. Serology for HIV infection, along with cultures or PCR tests for HSV should also be performed.
Patients with secondary syphilis have highly sensitive nontreponemal tests (RPR, VDRL). A prozone phenomenon can occur when the antitreponemal antibody titer is so elevated that the characteristic agglutination reaction cannot occur. When clinical suspicion for secondary syphilis is high and the nontreponemal serology is negative, the test should be repeated at additional dilutions (usually 1:10). 19 
Treatment
The treatment of choice for primary, secondary, or early latent syphilis is Benzathine penicillin at a dose of 2.4 million units given as a single intramuscular injection. 20 A nontreponemal antibody test should be obtained on the day of treatment to establish Sexually Transmitted Diseases 183 a baseline to monitor response. Patients coninfected with HIV do not require additional doses of penicillin. 19 Doxycycline is recommended as the main alternative for patients unable to take penicillin. The dosage is doxycycline 100 mg orally twice a day for 28 days. 19 Ceftriaxone and azithromycin have also been shown to be effective. Ceftriaxone is given in a dose of 1 to 2 g either intramuscularly or intravenously for 10 to 14 days and cross-reactivity to penicillin allergy is negligible ( 
